Skip to content

Ketone Labs Announces Potential Life-Saving Breakthrough in Treatment of Rare, Fatal Infant Disease

  1. Home
  2. In The News
  3. Ketone Labs Announces Potential Life-Saving Breakthrough in Treatment of Rare, Fatal Infant Disease

Ketone Labs Announces Potential Life-Saving Breakthrough in Treatment of Rare, Fatal Infant Disease

Salt Lake City, UT— 18 April, 2024 — Ketone Labs, the leader in ketone supplementation technology and distributor of goBHB, today revealed groundbreaking results suggesting the use of D/L-β-hydroxybutyric (D/L-βHBA) offers a lifeline in the treatment of Multiple Acyl-CoA Dehydrogenase Deficiency (MADD).

MADD is a devastating metabolic disorder that steals the ability of infants to turn food into energy. This cruel disease affects approximately 5,000 babies each year in the U.S. Until now, no hope existed – and tragically, most children with MADD succumbed to the disease.

A Miracle in the Making: XO Balance, D/L-βHBA

Hospitals across the nation have begun exploring the use of D/L-βHBA with MADD patients. Early findings paint a picture of hope: babies are defying expectations and starting to thrive.

“When doctors at Mount Sinai Hospital contacted us, we were humbled and astounded to learn one of our ketone technologies might save lives,” said Rob Rogers, co-founder of Ketone Labs. “We had no knowledge about this rare disease and the idea our work could transform the outlook for children with MADD was a powerful confirmation about the power of D/L-βHBA. This discovery opens a door to endless possibilities for the power of ketones in these types of rare diseases.”

Gary Millet, Ketone Labs co-founder, added, “We now want and need the world to understand the urgency and the heartbreak of MADD. This breakthrough shouldn’t remain a secret. We urge the research and philanthropic community to rally around this and give these children a future.”

Key Messages

  • A Glimmer of Hope: For a disease long considered a death sentence, promising results with D/L-βHBA offer the first potential treatment.
  • Lives on the Line: MADD is a crisis for thousands of families each year in the US – time is precious.
  • Ketone Labs’ Commitment to MADD Research: Ketone Labs is dedicated to advancing research on ketone supplementation for MADD and other metabolic disorders. The company is actively exploring collaborations with researchers and clinicians to bring this potential new therapy to patients.

About Ketone Labs

Ketone Labs is a leading distributor of goBHB ketones, providing high-quality ketone supplements to athletes, healthcare professionals, and individuals seeking to optimize their health. The company is committed to scientific research and education on the potential benefits of ketone supplementation.

For further information, please contact:
Ketone Labs Media Relations: Mackenzie@realketones.com
For more information on Product: https://ketonelabs.com

Disclaimer: This press release is for informational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional before starting any new dietary supplement regimen.